



PRIOR AUTHORIZATION REQUEST *Humira*

PATIENT: Name _____
Address: _____
City, State, Zip _____
D.O.B. _____
Member ID: _____

Prescriber: Name _____
Address _____
City, State, Zip _____
Phone _____
Fax _____
NPI _____

Medication Requested: _____ **Qty Requested:** _____

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please answer the following questions

1. Will the requested medication be used in combination with a BIOLOGIC or Targeted Synthetic disease-modifying antirheumatic drug?
 - Biologic DMARD
 - Targeted synthetic DMARD
 - Conventional synthetic DMARD
 - No, the requested medication will NOT be used in combination with another BIOLOGIC or Targeted Synthetic disease-modifying antirheumatic drug (DMARD)
2. Yes No Is the patient currently receiving an adalimumab product?
3. What is the diagnosis/ indication for use?
 - Rheumatoid arthritis – **Please answer questions 5, 6, 9 & 37**
 - Other – **Please answer question 4**
4. What is the indication or diagnosis?
 - Ankylosing spondylitis – **Please answer questions 9 & 38**
 - Crohn's disease – **Please answer questions 23, 27, 30, 31, 41 & 44**
 - Juvenile idiopathic arthritis (JIA) or Juvenile rheumatoid arthritis (JRA), (regardless of type of onset) (This includes patients with juvenile spondyloarthritis/active sacroiliac arthritis) – **Please answer questions 9, 20, 26, 29 & 40**
 - Plaque psoriasis – **Please answer questions 15, 18, 24, 28 & 41**
 - Psoriatic arthritis (PsA) – **Please answer question 42**
 - Psoriatic arthritis – **Please answer questions 8, 42**
 - Ulcerative colitis – **Please answer questions 19, 25, 43 & 44**
 - Hidradenitis suppurativa – **Please answer questions 18, 21 & 41**
 - Uveitis (including other posterior uveitides and panuveitis syndromes) – **Please answer questions 7, 22 & 47**
 - Spondyloarthritis (SpA), other subtypes (for example, undifferentiated arthritis, non-radiographic

**If you have any
questions, call:
800-753-2851**

PRIOR AUTHORIZATION REQUEST

Humira

axial SpA, reactive arthritis [Reiter's disease], arthritis associated with inflammatory bowel disease [IBD]) [NOTE: For AS or PsA, refer to the respective criteria above] – **Please answer questions 9 – 14 & 38**

- Behcet's disease – **Please answer questions 16, 32, 45 & 46**
 - Pyoderma gangrenosum – **Please answer questions 17, 18 & 46**
 - Sarcoidosis – **Please answer questions 33 – 35 & 46**
 - Scleritis or sterile corneal ulceration – **Please answer questions 22, 36 & 48**
 - Polymyalgia rheumatica (PMR)
 - All other indications or diagnoses – Please specify _____
5. Yes No Has the patient tried one conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months?
 6. Yes No Has the patient tried at least one biologic for at least 3 months?
 7. Yes No Has the patient tried one of the following therapies: periocular, intraocular, or systemic corticosteroids; immunosuppressives, or an etanercept or an infliximab product for uveitis?
 8. Yes No Is the requested medication prescribed by or in consultation with a rheumatologist or a dermatologist?
 9. Yes No Is the requested medication prescribed by or in consultation with a rheumatologist?
 10. Yes No Does the patient have arthritis primarily in the knees, ankles, elbows, wrists, hands and/or feet?
 11. Yes No Has the patient tried at least ONE conventional synthetic DMARD?
 12. Yes No Does the patient have axial spondyloarthritis?
 13. Yes No Does the patient have objective signs of inflammation, defined as: a C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory?
 14. Yes No Does the patient have objective signs of inflammation, defined as: sacroiliitis reported on magnetic resonance imaging (MRI)?
 15. Yes No Has the patient tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant?
 16. Yes No Has the patient tried at least ONE conventional therapy or at least one tumor necrosis factor inhibitor?
 17. Yes No Has the patient tried one other immunosuppressant for at least 2 months or was intolerant to one of these agents OR tried one systemic corticosteroid?
 18. Yes No Is the requested medication prescribed by or in consultation with a dermatologist?
 19. Yes No Has the patient had a trial of one systemic agent or a corticosteroid for ulcerative colitis?
 20. Yes No Has the patient tried one other agent for this condition or will be starting on the requested medication concurrently with methotrexate, sulfasalazine, or leflunomide?
 21. Yes No Has the patient tried ONE other therapy?
 22. Yes No Is the requested medication prescribed by or in consultation with an ophthalmologist?

**If you have any
questions, call:
800-753-2851**

PRIOR AUTHORIZATION REQUEST

Humira

23. Yes No Has the patient tried one other agent for Crohn's disease?
24. Yes No Has the patient already had a 3-month trial or previous intolerance to at least one biologic?
25. Yes No Does the patient have pouchitis AND has tried therapy with an antibiotic, probiotic, corticosteroid enema, or Rowasa (mesalamine) enema?
26. Yes No Does the patient have an absolute contraindication to methotrexate, suflasalazine, or leflunomide?
27. Yes No Has the patient tried corticosteroids, or is currently on corticosteroids, or are corticosteroids contraindicated in this patient?
28. Yes No Does the patient have a contraindication to methotrexate, as determined by the prescriber?
29. Yes No Does the patient have aggressive disease as determined by the prescriber?
30. Yes No Does the patient have enterocutaneous (perianal or abdominal) or rectovaginal fistulas?
31. Yes No Has the patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence)?
32. Yes No Does the patient have ophthalmic manifestations of Behcet's disease?
33. Yes No Has the patient tried at least ONE corticosteroid for this condition?
34. Yes No Has the patient tried at least one immunosuppressive agent, an infliximab product, chloroquine, or thalidomide?
35. Yes No Is the requested medication prescribed by or in consultation with a pulmonologist, ophthalmologist, or dermatologist?
36. Yes No Has the patient tried ONE other therapy for this condition?
37. Yes No Has the patient had a response, as determined by the prescriber?
38. Yes No Has the patient had a response, as determined by the prescriber?
39. Yes No Has the patient had a response to an adalimumab product, as determined by the prescriber?
40. Yes No Has the patient had a response, as determined by the prescriber?
41. Yes No Has the patient had a response to an adalimumab product, as determined by the prescriber?
42. Yes No Has the patient had a response, as determined by the prescriber?
43. Yes No Has the patient had a response, as determined by the prescriber?
44. Yes No Is the requested medication prescribed by or in consultation with a gastroenterologist?
45. Yes No Is the requested medication prescribed by or in consultation with a rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist?
46. Yes No Has the patient responded to therapy, as determined by the prescriber?
47. Yes No Has the patient responded to therapy, as determined by the prescriber?
48. Yes No Has the patient responded to therapy, as determined by the prescriber?

**If you have any
questions, call:
800-753-2851**



PRIOR AUTHORIZATION REQUEST
Humira

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 877-251-5896

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 800-753-2851